In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Incyte Corp (NASDAQ: INCY) closed at $103.43 in the last session, down -2.73% from day before closing price of $106.33. In other words, the price has decreased by -$2.73 from its previous closing price. On the day, 2.03 million shares were traded. INCY stock price reached its highest trading level at $107.54 during the session, while it also had its lowest trading level at $102.675.
Ratios:
We take a closer look at INCY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.93 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.96. For the most recent quarter (mrq), Quick Ratio is recorded 3.13 and its Current Ratio is at 3.20. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On November 03, 2025, Guggenheim Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $125.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 07 ’26 when Issa Mohamed Khairie sold 10,856 shares for $109.07 per share. The transaction valued at 1,184,064 led to the insider holds 66,132 shares of the business.
Stein Steven H sold 15,634 shares of INCY for $1,589,978 on Jan 05 ’26. The EVP & Chief Medical Officer now owns 34,203 shares after completing the transaction at $101.70 per share. On Jan 07 ’26, another insider, MOHAMED ISSA, who serves as the Officer of the company, bought 10,856 shares for $109.07 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INCY now has a Market Capitalization of 20305657856 and an Enterprise Value of 17417103360. As of this moment, Incyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.35, and their Forward P/E ratio for the next fiscal year is 13.30. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.22 while its Price-to-Book (P/B) ratio in mrq is 4.36. Its current Enterprise Value per Revenue stands at 3.619 whereas that against EBITDA is 13.152.
Stock Price History:
The Beta on a monthly basis for INCY is 0.83, which has changed by 0.46743035 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, INCY has reached a high of $112.29, while it has fallen to a 52-week low of $53.56. The 50-Day Moving Average of the stock is 1.33%, while the 200-Day Moving Average is calculated to be 28.14%.
Shares Statistics:
According to the various share statistics, INCY traded on average about 2.34M shares per day over the past 3-months and 2250540 shares per day over the past 10 days. A total of 196.13M shares are outstanding, with a floating share count of 194.34M. Insiders hold about 1.01% of the company’s shares, while institutions hold 103.85% stake in the company. Shares short for INCY as of 1767139200 were 10539631 with a Short Ratio of 4.51, compared to 1764288000 on 9149380. Therefore, it implies a Short% of Shares Outstanding of 10539631 and a Short% of Float of 7.57.
Earnings Estimates
The firm’s stock currently is rated by 16.0 analysts. The consensus estimate for the next quarter is $1.57, with high estimates of $1.9 and low estimates of $1.33.
Analysts are recommending an EPS of between $7.16 and $4.84 for the fiscal current year, implying an average EPS of $6.75. EPS for the following year is $7.7, with 20.0 analysts recommending between $9.33 and $5.38.
Revenue Estimates
According to 18 analysts,. The current quarter’s revenue is expected to be $1.35B. It ranges from a high estimate of $1.43B to a low estimate of $1.3B. As of. The current estimate, Incyte Corp’s year-ago sales were $1.18BFor the next quarter, 18 analysts are estimating revenue of $1.25B. There is a high estimate of $1.36B for the next quarter, whereas the lowest estimate is $1.19B.
A total of 21 analysts have provided revenue estimates for INCY’s current fiscal year. The highest revenue estimate was $5.06B, while the lowest revenue estimate was $4.92B, resulting in an average revenue estimate of $4.98B. In the same quarter a year ago, actual revenue was $4.24BBased on 20 analysts’ estimates, the company’s revenue will be $5.53B in the next fiscal year. The high estimate is $5.82B and the low estimate is $5.13B.
